Alchemab Therapeutics has appointed Dr Ben Porter-Brown as Chief Medical Officer to enhance the clinical development of their innovative antibody therapeutics pipeline. This move is aimed at accelerating their research efforts in the biotechnology sector.
Company Information
Company
Alchemab Therapeutics
Location
London, England, United Kingdom
About
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.
Don't miss Alchemab Therapeutics's next move
Get an email the moment Alchemab Therapeutics changes its leadership, hires an exec, or expands, usually minutes after it happens.
LondonBiotechnologyHealth CareTherapeuticsPharmaceutical